

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known				
				Application Number	09/781,882 10/658904			
				Filing Date	2/12/01			
				First Named Inventor	Rosana Kapeller-Libermann			
				Group Art Unit	1648 1653			
Examiner Name	To Be Assigned							
Sheet	1	of	1	Attorney Docket Number	35800/209014 (5800-69)			
U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear		
FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Office ³	Number ⁴	Kind Code (if known) ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T
re.re.	1	THOME, M. et al., Identification of CARDIAK, A RIP-like Kinase that Associates with Caspase-1, Current Biology, Vol. 8(15) 1988.						
Examiner Signature	R. Kapeller-Libermann				Date Considered	9/28/05		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2101882v1

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.

Please type a plus sign (+) inside this box →

Approved for
Patent and Trademark OfficePTO/SB/08A (10-88)
through 10/31/99. OMB 0654-0031
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/784,882 10/658904
		Filing Date	February 12, 2001
		First Named Inventor	Rosana Kapeller-Libermann
		Group Art Unit	1602 1653
		Examiner Name	Maryam Monshipouri, Ph.D.
Attorney Docket Number	MPI00-010P1RM		
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Kind Code ² Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
re.re.	B1	WO	89/55865	A1	Genesis Research and Development Corp.	11-04-1999	Title pages, 1-47, Figure pp. 1-14; Sequence Listing pp. 22-23, 95-98, 132-133, 165-166, 168-169 and International Search Report	
re.re.	B2	WO	00/08177	A2	Immunex Corporation	02-17-2000		
re.re.	B3	WO	00/08178	A2	Immunex Corporation	02-17-2000		
re.re.	B4	EP	1074617	A2	Helix Research Institute	02-07-2001	Pages 1-5, 48, 127-135, 139, 145-150, 165-180, 197-199, 205-207, 211-214, 354-356, 376-379, 388-393, 407-408, 421-422, 474, 580, 649, 795-796, 855, 975-976, 1031, 1108-1107, 1192, 1385-1388, 1418, 1530-1532, 1541, 155601557, 1561-1562, 1568, 1581, 1642, 2057, 2099, 2319-2320, 2332, 2394, 2407, 2452-2453, 2494, 2504, 2517, 2525, 2533-2537	
re.re.	B5	WO	01/38503	A2	Sugen, Inc.	05-31-2001	Title pages, 1-109, 117, 121, 128, 131, 138, 140, 149, 218-220, 223-228, 238, 256, 262-265, 280, 295-296, 299, 302, 308-311, 314-321, 325, 327-328, 333, 377-388, Sequence Listing 22/43, 39.43	
re.re.	B6	WO	01/57188	A2	Hyseq, Inc.	08-09-2001	Title pages, 1-99, 104, 107, 133, 149, 335-339, Search Report	
re.re.	B7	WO	01/81363	A1	SmithKline Beecham Corp.	11-01-2001	Title pages, 1-29, 37, 40-43, Sequence Listing pp 17/69, 18/69, 57/69-59/69 Search Report	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

Approver use through 10/31/99. OMB 0854-0031

Patent and Trademark U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/781,882
		Filing Date	February 12, 2001
		First Named Inventor	Rosana Kapeller-Libermann
		Group Art Unit	4652 1659
		Examiner Name	Maryam Monshipour, Ph.D.
		Attorney Docket Number	MP100-010P1RM
Sheet	1 of 1		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
R.R.	C2	Holland, Pamela M. et. al., "RIP4 is an Ankyrin Repeat-Containing Kinase Essential for Keratinocyte Differentiation" <i>Current Biology</i> Vol. 12, (August 20, 2002), pp. 1424-1428.	
R.R.	C3	Bähr, Corinna et. al., "DIK, A Novel Protein Kinase that Interacts with Protein Kinase Cδ" <i>The Journal of Biological Chemistry</i> Vol. 275, (November 17, 2000), pp. 36350-36357.	
R.R.	C4	Hattori, M. et. al., "The DNA Sequence of Human Chromosome 21" <i>Nature</i> Vol. 405 (May 18, 2000), pp. 311-319.	
R.R.	C5	Bloeker, H. et. al., "Homo sapiens mRNA; cDNA DKFZp434B2328 (from clone DKFZp434B2328); partial cds." February 18, 2000 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on September 5, 2002]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. AL137448.	

Examiner Signature	R. R. Monshipour	Date Considered	9/28/05
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.